Furthermore, in vitro treatment with dupilumab reduced proliferation and GATA3 upregulation in CD4+ T cells upon IL-4 stimulation, suggesting that dupilumab may inhibit the expansion of memory pathogenic Th2 cells in patients with CRS. Here, CD4 is linked to congenital rubella syndrome.